Alvogen Aims To Be First On EU Pazopanib

Rival To Novartis’ Votrient Filed For Several European Markets

 
• By Dave Wallace

Alvogen believes it is the first company to file for a generic pazopanib rival to Novartis’ Votrient oncology brand in Europe.

Starting_Block
Alvogen is aiming to be first off the blocks with generic pazopanib in Europe • Source: Shutterstock

More from Generics

More from Products